Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice

Yasutomo Miura; Mase Sato; Toshie Kuwahara; Tomoki Ebata; Yasuhiko Tabata; Hidetoshi Sakurai

doi:10.1371/journal.pone.0266391

. 2022 Apr 4;17(4):e0266391. doi: 10.1371/journal.pone.0266391

Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice

Yasutomo Miura ^1,², Mase Sato ¹, Toshie Kuwahara ³, Tomoki Ebata ², Yasuhiko Tabata ³, Hidetoshi Sakurai ^1,^*

Editor: Julie Dumonceaux⁴

PMCID: PMC8979463 PMID: 35377913

Abstract

Duchenne muscular dystrophy (DMD) is an intractable genetic muscular disorder characterized by the loss of DYSTROPHIN. The restoration of DYSTROPHIN is expected to be a curative therapy for DMD. Because muscle stem cells (MuSCs) can regenerate damaged myofibers with full-length DYSTROPHIN in vivo, their transplantation is being explored as such a therapy. As for the transplanted cells, primary satellite cells have been considered, but donor shortage limits their clinical application. We previously developed a protocol that differentiates induced pluripotent stem cells (iPSCs) to MuSCs (iMuSCs). To ameliorate the respiratory function of DMD patients, cell transplantation to the diaphragm is necessary but difficult, because the diaphragm is thin and rapidly moves. In the present study, we explored the transplantation of iMuSCs into the diaphragm. First, we show direct cell injection into the diaphragm of mouse was feasible. Then, to enhance the engraftment of the transplanted cells in a rapidly moving diaphragm, we mixed polymer solutions of hyaluronic acid, alginate and gelatin to the cell suspension, finding a solution of 20% dissolved hyaluronic acid and 80% dissolved gelatin improved the engraftment. Thus, we established a method for cell transplantation into mouse diaphragm and show that an injectable hyaluronic acid-gelatin solution enables the engraftment of iMuSCs in the diaphragm.

Introduction

Duchenne muscular dystrophy (DMD) is an X-linked genetic disease due to a mutation of DMD gene, which encodes DYSTROPHIN. DYSTROPHIN is part of the protein complex that connects the actin cytoskeleton to the extracellular matrix and contributes to muscle membrane stability [1]. DMD patients are usually diagnosed at 3–5 years old and lose walking ability at about 12 years old. In addition, patients will need respiratory support and suffer from cardiomyopathy in their early teens [2]. The main causes of death are heart failure, respiratory failure, and respiratory infection [3]. Currently, there is no curative treatment, and palliative therapy, such as corticosteroids, is used [4].

The restoration of DYSTROPHIN is a promising therapy for DMD, and several therapeutic approaches have been investigated, including exon-skipping oligonucleotides [5, 6], gene therapy [7] and cell transplantation [8]. While the other strategies aim to restore truncated versions of DYSTROPHIN, cell transplantation potentially regenerates myofibers with full-length DYSTROPHIN. Previous research on cell transplantation showed that the intramuscular injection of myoblasts and satellite cells regenerates normal myofibers in mice [9, 10] However, there is a shortage of muscle stem cell (MuSC) donors, and the cells are difficult to expand while maintaining their stemness and engraftment ability prior to the injection [11, 12]. As an alternative, the differentiation of induced pluripotent stem cells (iPSCs) into engraftable iPSC-derived MuSCs (iMuSCs) has been explored [13].

To ameliorate respiratory function in DMD, transplantation to the diaphragm, which is the main respiratory muscle, is necessary. MuSCs cannot pass through the vessel wall in intra-arterial transplantation [14], which makes direct cell injection into the muscle necessary. However, direct cell injection to the diaphragm is difficult due to the muscle’s thin dimension. Cell-sheet attachment is considered an effective method for cell delivery to the diaphragm [15], but the sheets fail to couple electromechanically with the host muscle [16].

In the present study, we investigated cell transplantation into the diaphragm by direct injection in DMD model mice. To enhance the engraftment efficiency, we injected the cells with a mixed polymer solution of hyaluronic acid and gelatin or alginate and gelatin to promote cell engraftment and proliferation in vivo [17, 18]. Our results provide a strategy for direct cell transplantation into the diaphragm of mice.

Materials and methods

Study approval

All animal experiments were performed in accordance with the guidelines of the animal experiment committee and recombinant DNA experiment committee at Kyoto University. The study design was reviewed and accepted by the CiRA Animal Experiment Committee prior to conducting any experiments (No.20-232).

Animals

The NOG-mdx mouse strain (NOD.Cg-Prkdc^scid Dmd^mdx il2rg^tm1Sug/Jic), which is an immunodeficient DMD model mice, was provided by CIEA (Kanagawa, Japan). C57BL/6NCrSlc (B6) mice were purchased from Simizu Laboratory Supplies Co., Ltd. (Kyoto, Japan). Transplantation experiments were performed on NOG-mdx mice 8–12 weeks old. C57BL/6-Tg (CAG-EGFP) [19] mice were purchased from Japan SLC (Sizuoka, Japan). Primary satellite cells were harvested from CAG-EGFP mice 6–7 weeks old and used as donor cells.

Cells

Primary satellite cells

A previous study reported that the monoclonal antibody SM/C 2.6, which is a specific mouse cell-surface marker of quiescent satellite cells and was kindly provided by Dr. So-ichiro Fukada (Osaka University), can be used to purify satellite cells from mouse skeletal muscle by flow cytometry (FCM) [20]. Muscle fibers were harvested from the limbs of CAG-EGFP mice 6–7 weeks old and dissociated with Collagenase type Ⅱ (CLASSⅡ, Worthington). SM/C 2.6 positive and CD31, CD45, Sca-1 triple negative cells were sorted using an Aria II (BD Biosciences) based on a previous report [20]. Isolated satellite cells from CAG-EGFP mice were detected as the GFP positive population by FCM (S1 Fig). A list of the antibodies used is provided in S1 Table.

Hu5/KD3

Hu5/KD3 is an immortalized myoblast cell clone [21] and was kindly provided by Dr. Naohiro Hashimoto (National Center for Geriatrics and Gerontology). To visualize the cells by fluorescence microscopy, a GFP-transgenic Hu5/KD3 line was established by a GFP-expressing piggyBac vector, PB-EF1α-EiP [22]. Hu5/KD3 and GFP-transgenic Hu5/KD3 were maintained in DMEM (Invitrogen) media supplemented with 20% fetal bovine serum (FBS, Biosera), 2% Ultroser G (Pall Corp.), 1% L-glutamine (Invitrogen), and 0.5% Penicillin Streptomycin Mixed Solution (nacalai tesque) on a collagen-coated dish.

Human iPSC culture and differentiation

The human iPSC lines Ff-WJ14s01 and 414C2 were used for the experiments. Ff-WJ14s01 (an HLA homozygous iPSC line with the most frequent haplotype in Japan, abbreviated as S01 in this manuscript) was established from cord blood cells by using episomal vectors, while 414C2 was established from purchased human dermal fibroblast as previously described [23]. S01 was generated under written consent with approval by the Kyoto University Graduate School and Faculty of Medicine Ethics Committee (approval numbers #E1762, #G567and #Rinsho71). Both S01 and 414C2 were labeled with a Venus reporter for PAX7, and then they were differentiated into iMuSCs as previously described [13, 24]. Briefly, the iPSCs were seeded in a Matrigel-coated 6-well plate and cultured with StemFit (AK02N, Ajinomoto) medium (1x10⁴ cells/well). At day 3, the medium was changed to CDMi medium supplemented with CHIR99021 (CHIR, Axon MedChem, Tocris) and SB431542 (SB, Sigma). CDMi medium is composed of IMDM (Invitrogen) and F12 (1X) Nutrient Mixture (Ham) (Invitrogen) at the ratio 1:1 supplemented with 1% BSA (Sigma), 0.5% Penicillin Streptomycin Mixed Solution, 1% CD Lipid Concentrate (Invitrogen), 1% Insulin-Transferrin Selenium (Invitrogen) and 450 μM 1-Thioglycerol (Sigma). Seven days later, the cells were passed to a Matrigel-coated dish with CDMi medium supplemented with SB and CHIR (1x10⁶ cells/6-cm dish). Seven days later, the cells were passaged to a Matrigel-coated 6-well plate with CDMi medium (8x10⁵ cells/well). Three days later, the medium was switched to SFO3 medium (Sanko-Junyaku) supplemented with IGF-1, bFGF, and HGF. At day 38 of the differentiation, the medium was switched to DMEM (Invitrogen) supplemented with 0.5% Penicillin Streptomycin Mixed Solution, 2 mM L-glutamine (nacalai tesque), 0.1 mM 2-ME, 2% Horse Serum (HS, Sigma), 5 μM SB and 10 ng/mL IGF-1. This medium was replaced with fresh medium of the same composition 3 times per week until day 84 of the differentiation. Afterwards, mature myotubes were observed, and PAX7-VENUS positive iMuSCs were sorted by FCM.

Flow cytometry sorting of muscle stem cells

After day 84 of the iMuSC induction, the cells were dissociated and sorted for the Venus reporter by FCM. The cells were dissociated with Collagenase G (500 μg/mL) (meiji), Collagenase H (100 μg/mL) (meiji) and DISPASE Ⅱ (0.3 mg/mL) (GODO SHUSEI) for 60 minutes, followed by 5 minutes with Accutase (Innovative Cell Technologies, Inc.) at 37°C and then filtered with a 40-μm mesh. To remove non-viable cells from the cell suspension, the suspension was layered on an OptiPrep (Merck) with DMEM containing 10% serum and centrifuged at 800xg for 20 minutes. The density of OptiPrep and DMEM containing 10% serum was higher than that of the viable cells, and after the centrifugation, non-viable cells were pelleted, macromolecular material or enzymes remained in the supernatant, and viable cells were recognized as an interfacial band. Thus, viable cells were harvested at the interfacial band and diluted with DMEM containing 10% serum, followed by centrifugation at 400xg for 10 minutes. Finally, the cells were resuspended with HBSS buffer containing 1% bovine serum albumin (Sigma) and Propidium Iodide (0.5 μg/mL) (Sigma). Venus-Pax7 positive cells were sorted using the Aria II.

Preparation of injectable mixed polymer solution

Gelatin (Nitta Gelatin Inc.), hyaluronic acid (Denka) and alginate (KIMICA Inc.) were dissolved in injectable media, 1% w/v at 37°C. Polymer solutions were prepared by mixing alginate with gelatin (A/G solution) or hyaluronic acid with gelatin (H/G solution) and added to the cell suspension. The volumetric ratio of the injectable solution (mixed polymer solution and cell suspension) was 4:1.

Measurement velocity of polymer solution

Each A/G and H/G solution was dropped onto a tilted glass slide, and the distance travelled by the solution in 10 seconds was measured. This measurement for each polymer solution was performed 3 times repeatedly.

Transplantation to the diaphragm

All mice were anesthetized using 2% Isoflurane. Laparotomy was performed, and cell suspension with or without mixed polymer solutions was injected with a syringe and 33G needle (ITO CORPORATION) at the edge of the diaphragm by stereomicroscopy via the abdomen. Freshly sorted cells were resuspended, and 1×10⁴ cells per injection site (primary satellite cells) or 1×10⁵ cells per injection site (GFP-transgenic Hu5/KD3 and iMuSCs) were injected. The injection volume per site was 10 μL. Injection into the diaphragm was recognized by swelling of the injection site.

Transplantation to the tibialis anterior

All mice were anesthetized using isoflurane. After exposure of the tibialis anterior (TA), cryoinjury [24] was performed 3 times by direct contact for 12 seconds each time, followed by the transplantation of 1×10⁶ GFP-transgenic Hu5/KD3 cells per TA.

Immunocytochemistry

Cultured cells were fixed with 2% Paraformaldehyde (PFA, nacalai tesque) in Phosphate buffer solution (PBS, nacalai tesque) for 10 min on ice, washed 2 times with PBS for 10 minutes and blocked with Blocking One (nacalai tesque) for 1 hour at 4°C on a shaker. Then, the samples were incubated with primary antibodies diluted in 10% Blocking One/PBS containing 0.2% Triton-X (nacalai tesque) (PBS-T) overnight at 4°C. The following day, the samples were washed 3 times for 10 minutes with 0.2% PBS-T and incubated with the corresponding secondary antibodies and DAPI (1:5000) at room temperature on the shaker. Finally, the samples were observed under a BZ-X700 microscope (KEYENCE).

A list of the antibodies used is provided in S1 Table.

Immunohistochemistry

The TA and diaphragm were harvested and cryopreserved. Cryosections (10–12 μm) were fixed with 4% PFA for 20 min, washed 2 times with PBS for 5 minutes, blocked with Blocking One (nacalai tesque) for 1 hour at room temperature, and incubated with primary antibodies diluted in Can get Signal B solution (TOYOBO) overnight at 4°C. The samples were washed 3 times for 10 minutes with 0.2% PBS-T and incubated with the corresponding secondary antibodies and DAPI (1:5000) for 1 hour at room temperature. Then the slides were washed 1 time for 5 minutes with PBS-T and 2 times for 5 minutes with PBS. After that, the samples were mounted in Aqua-Poly-Mount mounting medium (Polyscience). Sections were observed under an LSM710 (Carl Zeiss) or FV3000 (Olympus) confocal microscope. To detect human nuclei and myofibers by optical microscopy, the cryosections were stained with 3,3’-Diaminobenzidine (DAB) and eosin. The cryosections were also stained with anti-h-Nuclei antibody as the primary antibody and anti-mouse IgG1 HRP antibody, followed by 3 washes with PBS-T for 10 minutes each time. Then, DAB staining was performed using the Peroxidase Stain DAB Kit (nacalai tesque) according to the manufacturer’s protocol. After that, the samples were washed with water for 20 minutes, stained with 0.5% Eosin Y-solution (Merck) for 6 minutes, and washed with water again for 6 minutes. The samples were mounted in MOUNT-QUICK (DAIDO SANGYO) and observed under a BX51 microscope (Olympus).

A list of the antibodies used is provided in S1 Table.

Observation of GFP signals

Mice were sacrificed, and the diaphragm was harvested and immediately observed under a fluorescence stereomicroscope (Leica M205FA). After the observation, the sample was fixed with 4% PFA for 30 minutes at 4°C and 30% sucrose overnight at 4°C, followed by cryopreservation.

Statistical analysis

All statistical analyses were performed using GraphPad Prism version 9.2.0 for Mac OS (GraphPad Software). Data are expressed as the mean ± SEM. Differences between two groups were analyzed using the two-tailed Student’s t test, and differences between three or more groups were analyzed by ANOVA (analysis of variance) with Tukey’s range test for multiple comparisons. Significant differences were considered as p < 0.05.

Engraftment efficiency analysis

The TA and diaphragm were sectioned every 10–12 μm and stained. Myofibers derived from engrafted cells were recognized as h-SPECTRIN positive fibers. To quantify the number of h-SPECTRIN positive fibers, TA samples 2 weeks after the transplantation and diaphragm samples 4 weeks after were analyzed using an SM710 (Carl Zeiss) or FV3000 (Olympus) confocal microscope. The number of detected h-SPECTRIN-positive fibers in one section was recorded as the number of engrafted myofibers.

Validation of cell proliferation in vitro after passing through the transplantation needle

The condition of passaging was divided into three groups: passing through the 33G needle without polymer solution and then cultured, passing through the needle with polymer solution and then cultured, and cultured without passing through the needle. Three types of cells, primary satellite cells, Hu5/KD3 and iMuSCs, were seeded into 3 wells each. The number of cells was counted by trypan blue staining before cell confluency, and the cell proliferation was compared within the three groups.

Results

Primary satellite cells regenerate dystrophic diaphragm in NOG-mdx mice

To investigate if cell transplantation into the diaphragm is feasible, we used mouse primary satellite cells. After isolating primary satellite cells from the limb muscles of CAG-EGFP mice by FCM, the purity of the isolated cells was validated by myogenic marker expression after 3 days of culture (Fig 1A). Isolated cells were GFP positive (S1 Fig). More than 90% of cells were PAX7 and/or MYOD1 positive (Fig 1B), indicating good purity for the transplantation experiment. The cells were then transplanted into NOG-mdx mice by direct injection through the edge of the diaphragm. GFP signals were detected in the transplanted area (Fig 1C), and DYSTROPHIN positive fibers expressing GFP derived from the transplanted cells were detected (Fig 1D). In total, these results demonstrated that MuSC transplantation into the diaphragm of mice is feasible.

Fig 1 — (A) Immunocytochemistry staining of isolated primary satellite cells after 3 days of culture. GFP (green), DAPI (blue), PAX7 (red), MYOD1 (white). Scale bars, 100 μm. (B) Quantification of PAX7+MYOD–, PAX7+MYOD+, and PAX7–MYOD+ cell populations after 3 days of culturing primary satellite cells. Data show the mean ± SD. n = 3. (C) Representative images of the diaphragm by fluorescence stereomicroscopy 4 weeks after the transplantation. The cells were injected to the left side of the diaphragm, and vehicle was injected to the right side. Scale bars, 2 mm. Arrowheads show injection sites. (D) Representative immunohistochemistry staining of a cryosection. Sections were stained with anti-DYSTROPHIN antibody (red) and anti-GFP antibody (green). Nuclei were stained with DAPI (blue). Scale bars, 50 μm.

Transplantation of human immortalized myoblasts into the diaphragm shows limited engraftment

To confirm if human myogenic cells can be transplanted into the diaphragm, Hu5/KD3 [21], an immortalized human myoblast line, was tested. Hu5/KD3 has the potential to engraft into the skeletal muscle of immunodeficient mice to induce muscle regeneration in vivo [21]. To visualize the engrafted area as a whole mount sample, GFP-transgenic Hu5/KD3 was generated and transplanted into the diaphragm of NOG-mdx mice. GFP was expressed homogenously, and the cells were MYOD1 positive but PAX7 negative (Fig 2A). Although GFP was expressed in whole mount samples (Fig 2B upper panel) and DYSTROPHIN positive fibers were detected 4 weeks after the transplantation (Fig 2B lower panel), the magnitudes were less than with the transplantation of mouse primary cells (Fig 2C), suggesting Hu5/KD3 cells need further modification to enhance their engraftment potential in the diaphragm of NOG/mdx mice.

Fig 2 — (A) Immunocytochemistry staining of GFP-transgenic Hu5/KD3 in culture. Cells were stained with anti-PAX7 antibody (red), anti-MYOD1 antibody (white), and DAPI (blue). Scale bars, 100 μm. (B) A representative fluorescence stereomicroscopy image of the diaphragm 4 weeks after the transplantation of GFP-transgenic Hu5/KD3 (upper panel). Scale bar, 2 mm. Arrowheads show GFP. Immunohistochemistry staining of the image (lower panel). The image was stained with anti-DYSTROPHIN antibody (red) and anti-GFP antibody (green). Nuclei were stained with DAPI (blue). Scale bars, 50 μm. (C) Quantification of DYSTROPHIN positive fibers in the transplanted areas. Data show the mean ± SEM (two-tailed Student’s t-test; ****p<0.0001) and are from three independent experiments. Three mice were used in one experiment. There were in total 87 primary satellite cells and 78 GFP transgenic Hu5/KD3 cells in the respective GFP areas.

Cell suspension with mixed polymer solution improves the engraftment efficiency of Hu5/KD3

During the cell transplantation, we noticed that the injected cell suspension flowed out of the diaphragm due to rapid respiratory movement. We hypothesized that this effect could contribute to the low engraftment efficiency. Previous studies on cardiomyocyte transplantation have reported that gelatin enhances the engraftment of transplanted cells [17, 25] and that a mixed polymer solution composed of alginate and gelatin with ferric irons improves cell survival and proliferation in vitro and in vivo [26]. In addition to gelatin and alginate, hyaluronic acid is a viscous material that has been used in clinical practice [27].

We hypothesized that the viscosity of the mixed polymer solution may affect cell migration. We therefore evaluated the viscosity of mixed polymer solutions of different hyaluronic acid/gelatin and alginate/gelatin composition on tilted glass (Fig 3A). To identify the most suitable mixed polymer solution condition for myogenic cell transplantation, Hu5/KD3 with mixed polymer solution was injected into the tibialis anterior (TA) muscle of NOG-mdx mice. Two weeks after the transplantation, h-SPECTRIN positive fibers were counted to assess the engrafted cells because the SPECTRIN signal was stronger than the DYSTROPHIN signal (Fig 3B arrowheads). H2G8 (20% dissolved hyaluronic acid and 80% dissolved gelatin) and A2G8 (20% dissolved alginate and 80% dissolved gelatin) improved the engraftment efficiency significantly (Fig 3C and 3D). Compared to medium condition, A10 and A5G5 reduced the engraftment efficiency significantly. Moreover, a large gap was observed between host myofibers with the A10 (100% dissolved alginate) transplantation, suggesting alginate prevented migration of the engrafted cells because it is not biodegradable, unlike hyaluronic acid and gelatin (Fig 3E).

Fig 3 — (A) Velocities of mixed polymer solutions along a tilted glass. Data shown are from three independent experiments. (B) Immunohistochemistry staining 2 weeks after Hu5/KD3 transplantation into the TA. Sections were stained with anti-DYSTROPHIN antibody (green), anti-h-SPECTRIN antibody (red) and anti-h-NUCLEI antibody (white). Nuclei were stained with DAPI (blue). Scale bars, 50 μm. Yellow arrowheads show the DYSTROPHIN signal was weaker than the signal in myofibers. (C) Immunohistochemistry staining 2 weeks after Hu5/KD3 transplantation into the TA. Sections were stained with anti-DYSTROPHIN antibody (green), anti-h-SPECTRIN antibody (red) and anti-h-NUCLEI antibody (white). Nuclei were stained with DAPI (blue). Scale bars, 50 μm. (D) Quantification of h-SPECTRIN positive fibers derived from the engrafted cells. Data show the mean ± SEM (ANOVA with Tukey’s multiple comparison test). Each mark above the bars indicates a statistically significant difference. Data shown are from three independent experiments. The number of sections in each analysis is 44 or 45. (E) Immunohistochemistry and eosin staining. Engrafted cells were stained with h-NUCLEI (blown). Arrowheads show engrafted cells. Scale bars, 100 μm. For the mixed polymer solution names, H = hyaluronic acid, A = alginate, G = gelatin, and numbers indicate the ratios of the material in the mixed polymer solution.

Mixed hyaluronic acid-gelatin solution reduces the frequency of iMuSC engraftment failure in the diaphragm of NOG-mdx mice

To investigate if mixed polymer solutions can improve the engraftment efficiency of cell transplantation into the diaphragm, GFP-transgenic Hu5/KD3 with A2G8, H2G8 or no polymer solution (Medium) was injected. However, we found no significant difference between the three groups (Fig 4A and 4B). Next, the effect of the mixed polymer solutions on the iMuSC transplantation was assessed. We isolated iMuSCs by FCM after differentiating iPSCs with a knock-in Venus reporter for PAX7 gene (S2 Fig) and transplanted them into the diaphragm of NOG-mdx mice with H2G8, A2G8 or culture medium [13, 24]. Four weeks after the transplantation, the iMuSC engraftment was analyzed by the number of h-SPECTRIN positive myofibers (Fig 4C). While the inclusion of H2G8 significantly increased the number of h-SPECTRIN positive fibers, the iMuSC engraftment was still very low (Fig 4D). However, when we assessed the proportion of h-SPECTRIN positive fibers per section, we found H2G8 reduced the frequency of engraftment failure, as the proportion of no h-SPECTRIN positive fibers was 0.15 with H2G8 but 0.69 and 0.56, respectively, with A2G8 and Medium (Fig 4E).

Fig 4 — (A) A fluorescence stereomicroscopy image of the diaphragm 2 weeks after the transplantation of GFP-transgenic Hu5/KD3. Scale bars, 2 mm. Arrowheads show GFP. Data shown are from five independent experiments. Each of ten unilateral diaphragms were analyzed in the three groups (Medium, A2G8, H2G8). (B) Quantification of GFP signals in the unilateral diaphragm. Horizontal and vertical lines show means ± SEM (ANOVA with Tukey’s multiple comparison test). (C) Immunohistochemistry staining 4 weeks after the iMuSC transplantation. Sections were stained with anti-h-SPECTRIN antibody (green), anti-h-NUCLEI antibody (red), and anti-LAMININ α2 antibody (white). Nuclei were stained with DAPI (blue). Scale bars, 50 μm. (D) Quantification of h-SPECTRIN positive fibers 4 weeks after the iMuSC transplantation. Data show the mean ± SEM (ANOVA with Tukey’s multiple comparison test). ****p<0.0001. The number of sections is 38 (H2G8), 36 (A2G8) and 41 (Medium). (E) A histogram of h-SPECTRIN positive fibers per cryosection. The X-axis represents the number of h-SPECTRIN positive fibers in a single section, and the Y-axis represents the number of h-SPECTRIN positive fibers in a single section over all sections.

Mixed hyaluronic acid-gelatin solution improves the proliferation of iMuSCs

It is reported that mechanical stress during flow through a transplantation needle affects cell viability and proliferation [28]. Since we used a 33G needle, cell proliferation after passing through the needle was analyzed with or without H2G8. Passing through the needle reduced the proliferation of iMuSCs in culture without H2G8. However, H2G8 improved the proliferation to that without the needle flow (Fig 5A). Mouse primary satellite cells also showed reduced proliferation after passing through the needle but did not benefit significantly from H2G8 (Fig 5B). On the other hand, the proliferation of Hu5/KD3 was not affected by passing through the needle, which might be due to the immortality of this line (Fig 5C).

Fig 5 — (A) Number of iMuSCs 3 days after passage. The seeding cell number was 1.5 x 10⁴ cells/well. ‘Syringe’ describes cells passaged after passing through the needle; ‘H2G8 and Syringe’ describes cells passaged after passing through the needle with H2G8; and ‘Medium’ describes cells passaged without passing through the needle. (B) Number of mouse primary satellite cells 3 days after passage. The seeding cell number was 2.1 x 10⁴ cells/well. (C) Number of Hu5/KD3 cells 3 days after passage. The seeding cell number was 2.1 x 10⁴ cells/well. Data show the mean ± SEM (ANOVA with Tukey’s multiple comparison test). *p<0.05, **p<0.1; n = 3.

Discussion

In this study, we demonstrated iMuSC transplantation into the diaphragm of DMD model mice. First, we showed that transplantation by direct injection was feasible. Then, we found that a polymer mixture composed of gelatin and hyaluronic acid improved the engraftment efficiency.

Our results using mouse primary satellite cells demonstrated that stereomicroscopy with a tiny needle (33G) for the transplantation resulted in MuSCs regenerating skeletal muscle with intact DYSTROPHIN in the diaphragm. To ameliorate the respiratory function of DMD patients, the transplantation of MuSCs to the diaphragm is necessary, and iMuSCs will solve any donor shortages. However, current iMuSC differentiation methods have poor efficiency and need a long time. Therefore, we first investigated our transplantation protocol using immortalized human myoblasts, Hu5/KD3, which, like iMuSCs, are much easier to proliferate than primary MuSCs and can engraft into the skeletal muscle of immunodeficient mice to regenerate skeletal muscle. Although GFP-transgenic Hu5/KD3 engrafted into the diaphragm, the number of regenerated myofibers derived from the engrafted cells was less than that of primary satellite cells. It is well known that freshly isolated primary satellite cells have vigorous regeneration potential, but cultured primary satellite cells show lower regeneration potential [12]. Since Hu5/KD3 cells are PAX7-negative, MYOD-positive myoblasts, the difference of the regeneration potential between freshly isolated satellite cells and myoblasts might explain their low engraftment efficiency. Another possibility is differences in the extracellular matrix between in vivo satellite cells and in vitro cultured Hu5/KD3, which may affect the proliferation [29, 30].

In addition, the movement of the diaphragm might affect the engraftment efficiency. The diaphragm contracts very quickly, especially in mice, who have a respiration rate of 150–200 beats per minute. Contraction causes the injection medium to flow out of the injection hole. We hypothesized that cell retention at the injection site is important for the engraftment efficiency and viscous materials, such as polymer solutions and hydrogels, may enhance the cell retention. Gelatin, alginate and hyaluronic acid are viscous materials used in clinical practice. A previous report showed that transplanting murine pre-osteoblasts with a mixed polymer solution of gelatin and alginate that physically interacts with ferric ions to improve cell retention in the transplanted area [26]. Another study reported that hyaluronic acid increases the viability of neural stem cells in vivo [31]. We tested the engraftment efficiency with injectable polymer solution by transplanting Hu5/KD3 into the TA and found two types, H2G8 (20% dissolved hyaluronic acid and 80% dissolved gelatin) and A2G8 (20% dissolved alginate and 80% dissolved gelatin), improved the engraftment efficiency significantly. In contrast, the number of h-SPECTRIN positive fibers seen when including A10 (100% dissolved alginate) or A5G5 (50% dissolved alginate and 50% dissolved gelatin) was much less, and in the case of A10 the engrafted cells were detected in gaps between the myofibers, which indicated that cell migration was prevented because alginate is not biodegradable in vivo.

Cell transplantation into the diaphragm of mice has never been reported. Indeed, we found it difficult to transplant iMuSCs into the diaphragm, and more than half of our experiments resulted in no engraftment. In contrast, for the Hu5/KD3 transplantation, all experiments resulted in at least one engraftment site if using the same transplantation procedure for primary satellite cells. These observations suggested the cell viability of Hu5 and iMuSCs after the transplantation was different. Hu5/KD3, which is immortalized by the transduction of hTERT, CDK4R24C and cyclin D1, showed no change in cell proliferation after passing through the transplantation needle, whereas both primary satellite cells and iMuSCs showed reduced proliferation. Furthermore, because iMuSCs are not immortalized and not obtained in vivo, they may have more difficulty to engraft in the diaphragm after passing through the transplantation needle. H2G8 benefited the engraftment slightly, suggesting H2G8 might prevent cell damage during the injection. Therefore, the inclusion of H2G8 is one step in the optimization of iMuSC transplantation into the diaphragm.

Regardless, despite the inclusion of H2G8, the engraftment efficiency of iMuSCs was still much less than that of primary satellite cells. Moreover, in the case of the diaphragm, H2G8 only reduced the frequency of iMuSC engraftment failure. Further optimization of the cell transplantation, such as the addition of some factor, such as glutamine, Wint7a [15], glycine [32], or uPAR [33], and higher purification of the iMuSCs are warranted [34].

Conclusion

In summary, we demonstrated that cell transplantation into the diaphragm is feasible by direct injection and that the inclusion of a mixed hyaluronic acid-gelatin solution reduces the frequency of failed iMuSC transplantations into the diaphragm. These findings will contribute to the study of cell transplantations via local injections.

Supporting information

S1 Fig. FCM analysis of isolated primary satellite cells from mice.

(A) FCM analysis of isolated cells from B6 mice (left panel) and GFP expression (right panel). (B) FCM analysis of isolated primary satellite cells from CAG-EGFP mice (left panel) and GFP expression (right panel).

(TIF)

Click here for additional data file.^{(362.3KB, tif)}

S2 Fig. FCM analysis after differentiating iPSCs with a knock-in Venus reporter for PAX7 gene.

(TIF)

Click here for additional data file.^{(249.2KB, tif)}

S1 Table. A list of antibodies used.

(TIF)

Click here for additional data file.^{(179.3KB, tif)}

Acknowledgments

We would like to thank Akitsu Hotta for providing GFP-expressing piggy-Bac vector; So-ichiro Fukada for providing SM/C 2.6 antibody and the frozen stock of mouse primary satellite cells; Kanae Mitsunaga for her constant help with the FACS experiments; Syunsuke Kihara for his help with the microscopy analysis; Megumi Goto for technical assistance; and Peter Karagiannis for proofreading the manuscript.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by a grant from the Core Center for iPS Cell Research (JP21bm0104001), Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED) to H.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.Roberts RG. Dystrophins and dystrobrevins. Genome Biology. 2001;2(4):reviews3006.1. doi: 10.1186/gb-2001-2-4-reviews3006 [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013;14(6):373–8. Epub 2013/04/24. doi: 10.1038/nrg3460 . [DOI] [PubMed] [Google Scholar]
3.Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121–5. Epub 2012/10/26. ; PubMed Central PMCID: PMC3476854. [PMC free article] [PubMed] [Google Scholar]
4.McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–61. Epub 2017/11/28. doi: 10.1016/S0140-6736(17)32160-8 . [DOI] [PubMed] [Google Scholar]
5.Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8(10):918–28. Epub 2009/08/29. doi: 10.1016/S1474-4422(09)70211-X ; PubMed Central PMCID: PMC2755039. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Echevarría L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163–r72. Epub 2018/05/18. doi: 10.1093/hmg/ddy171 . [DOI] [PubMed] [Google Scholar]
7.Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther. 2018;26(10):2337–56. Epub 2018/08/11. doi: 10.1016/j.ymthe.2018.07.011 ; PubMed Central PMCID: PMC6171037. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Sun C, Serra C, Lee G, Wagner KR. Stem cell-based therapies for Duchenne muscular dystrophy. Exp Neurol. 2020;323:113086. Epub 2019/10/23. doi: 10.1016/j.expneurol.2019.113086 ; PubMed Central PMCID: PMC6899334. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature. 1989;337(6203):176–9. Epub 1989/01/12. doi: 10.1038/337176a0 [DOI] [PubMed] [Google Scholar]
10.Xu X, Wilschut KJ, Kouklis G, Tian H, Hesse R, Garland C, et al. Human Satellite Cell Transplantation and Regeneration from Diverse Skeletal Muscles. Stem Cell Reports. 2015;5(3):419–34. Epub 2015/09/10. doi: 10.1016/j.stemcr.2015.07.016 ; PubMed Central PMCID: PMC4618654. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Ikemoto M, Fukada S, Uezumi A, Masuda S, Miyoshi H, Yamamoto H, et al. Autologous transplantation of SM/C-2.6(+) satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Mol Ther. 2007;15(12):2178–85. Epub 2007/08/30. doi: 10.1038/sj.mt.6300295 . [DOI] [PubMed] [Google Scholar]
12.Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005;309(5743):2064–7. Epub 2005/09/06. doi: 10.1126/science.1114758 . [DOI] [PubMed] [Google Scholar]
13.Zhao M, Tazumi A, Takayama S, Takenaka-Ninagawa N, Nalbandian M, Nagai M, et al. Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model. Stem Cell Reports. 2020;15(1):80–94. Epub 2020/07/04. doi: 10.1016/j.stemcr.2020.06.004 ; PubMed Central PMCID: PMC7363940. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010;120(1):11–9. Epub 2010/01/07. doi: 10.1172/JCI40373 ; PubMed Central PMCID: PMC2798695. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Han WM, Mohiuddin M, Anderson SE, García AJ, Jang YC. Co-delivery of Wnt7a and muscle stem cells using synthetic bioadhesive hydrogel enhances murine muscle regeneration and cell migration during engraftment. Acta Biomater. 2019;94:243–52. Epub 2019/06/23. doi: 10.1016/j.actbio.2019.06.025 ; PubMed Central PMCID: PMC6642840. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Masumoto H, Ikuno T, Takeda M, Fukushima H, Marui A, Katayama S, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Scientific reports. 2014;4(1):1–7. doi: 10.1038/srep06716 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Nakajima K, Fujita J, Matsui M, Tohyama S, Tamura N, Kanazawa H, et al. Gelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial Infarction. PLoS One. 2015;10(7):e0133308. Epub 2015/07/18. doi: 10.1371/journal.pone.0133308 ; PubMed Central PMCID: PMC4505846. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Xu L, Guo Y, Huang Y, Xu Y, Lu Y, Wang Z. Hydrogel materials for the application of islet transplantation. J Biomater Appl. 2019;33(9):1252–64. Epub 2019/02/23. doi: 10.1177/0885328219831391 . [DOI] [PubMed] [Google Scholar]
19.Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. ’Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997;407(3):313–9. Epub 1997/05/05. doi: 10.1016/s0014-5793(97)00313-x . [DOI] [PubMed] [Google Scholar]
20.Fukada S, Higuchi S, Segawa M, Koda K, Yamamoto Y, Tsujikawa K, et al. Purification and cell-surface marker characterization of quiescent satellite cells from murine skeletal muscle by a novel monoclonal antibody. Exp Cell Res. 2004;296(2):245–55. Epub 2004/05/20. doi: 10.1016/j.yexcr.2004.02.018 . [DOI] [PubMed] [Google Scholar]
21.Shiomi K, Kiyono T, Okamura K, Uezumi M, Goto Y, Yasumoto S, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene therapy. 2011;18(9):857–66. doi: 10.1038/gt.2011.44 [DOI] [PubMed] [Google Scholar]
22.Matsui H, Fujimoto N, Sasakawa N, Ohinata Y, Shima M, Yamanaka S, et al. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. PloS one. 2014;9(8):e104957. doi: 10.1371/journal.pone.0104957 [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409–12. Epub 2011/04/05. doi: 10.1038/nmeth.1591 . [DOI] [PubMed] [Google Scholar]
24.Nalbandian M, Zhao M, Sasaki-Honda M, Jonouchi T, Lucena-Cacace A, Mizusawa T, et al. Characterization of hiPSC-Derived Muscle Progenitors Reveals Distinctive Markers for Myogenic Cell Purification Toward Cell Therapy. Stem Cell Reports. 2021. doi: 10.1016/j.stemcr.2021.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Tabei R, Kawaguchi S, Kanazawa H, Tohyama S, Hirano A, Handa N, et al. Development of a transplant injection device for optimal distribution and retention of human induced pluripotent stem cellderived cardiomyocytes. J Heart Lung Transplant. 2019;38(2):203–14. Epub 2019/01/30. doi: 10.1016/j.healun.2018.11.002 . [DOI] [PubMed] [Google Scholar]
26.Anamizu M, Tabata Y. Design of injectable hydrogels of gelatin and alginate with ferric ions for cell transplantation. Acta Biomater. 2019;100:184–90. Epub 2019/10/08. doi: 10.1016/j.actbio.2019.10.001 . [DOI] [PubMed] [Google Scholar]
27.Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23(12):H41–56. Epub 2011/03/12. doi: 10.1002/adma.201003963 ; PubMed Central PMCID: PMC3730855. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A. 2012;18(7–8):806–15. Epub 2011/10/21. doi: 10.1089/ten.TEA.2011.0391 ; PubMed Central PMCID: PMC3313609. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Ishii K, Sakurai H, Suzuki N, Mabuchi Y, Sekiya I, Sekiguchi K, et al. Recapitulation of Extracellular LAMININ Environment Maintains Stemness of Satellite Cells In Vitro. Stem Cell Reports. 2018;10(2):568–82. Epub 2018/01/18. doi: 10.1016/j.stemcr.2017.12.013 ; PubMed Central PMCID: PMC5830886. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Boonen KJ, Rosaria-Chak KY, Baaijens FP, van der Schaft DW, Post MJ. Essential environmental cues from the satellite cell niche: optimizing proliferation and differentiation. Am J Physiol Cell Physiol. 2009;296(6):C1338–45. Epub 2009/03/27. doi: 10.1152/ajpcell.00015.2009 . [DOI] [PubMed] [Google Scholar]
31.Zarei-Kheirabadi M, Sadrosadat H, Mohammadshirazi A, Jaberi R, Sorouri F, Khayyatan F, et al. Human embryonic stem cell-derived neural stem cells encapsulated in hyaluronic acid promotes regeneration in a contusion spinal cord injured rat. Int J Biol Macromol. 2020;148:1118–29. Epub 2020/01/27. doi: 10.1016/j.ijbiomac.2020.01.219 . [DOI] [PubMed] [Google Scholar]
32.Lin C, Han G, Ning H, Song J, Ran N, Yi X, et al. Glycine Enhances Satellite Cell Proliferation, Cell Transplantation, and Oligonucleotide Efficacy in Dystrophic Muscle. Mol Ther. 2020;28(5):1339–58. Epub 2020/03/27. doi: 10.1016/j.ymthe.2020.03.003 ; PubMed Central PMCID: PMC7210708. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Elhussieny A, Nogami K, Sakai-Takemura F, Maruyama Y, Takemura N, Soliman WT, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR). Stem Cell Res Ther. 2021;12(1):532. Epub 2021/10/11. doi: 10.1186/s13287-021-02594-1 ; PubMed Central PMCID: PMC8501581. [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Llufrio EM, Wang L, Naser FJ, Patti GJ. Sorting cells alters their redox state and cellular metabolome. Redox Biol. 2018;16:381–7. Epub 2018/04/09. doi: 10.1016/j.redox.2018.03.004 ; PubMed Central PMCID: PMC5952879. [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0266391.r001

Decision Letter 0

Julie Dumonceaux

29 Sep 2021

PONE-D-21-27260Injectable hyaluronic acid-gelatin solution enhances the engraftment efficiency of human iPS cell-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model micePLOS ONE

Dear Dr. Sakurai

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I am returning your manuscript with 2 reviews. The reviewers came to different conclusions about the article, as you will see. After reading the reviews and looking at the manuscript, my decision is "Major Revision". In particular, we would expect a revised manuscript to address cell viability after going through needles and experimental details (including N values, controls used and statistical analysis). In addition, the conclusions are not fully supported by the data and should be revised, as well as the title.This is not to say, however, that we consider any other concerns raised by our referees to be any less important.

Please submit your revised manuscript by 13 November 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Julie Dumonceaux

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

[This work was supported by a grant from the Core Center for iPS Cell Research (JP21bm0104001), Research Center Network for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED) to H.S.]

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting manuscript from an excellent laboratory addressing and important bottleneck in muscle cell therapy, i.e. delivery of myogenic cells to the diaphragm. The manuscript reads well and and the figures are also well presented (just occasional spelling mistakes).

My main concerns (which are easily addressable) are:

1) If diaphragm movements affect cell engraftment, why is this not impacting on mouse MuSC engraftment as well?

2) Authors use a 33G needle for their injections. This is a very small gauge which could potentially lysate the cell suspension being delivered. As human cells are larger in size than mouse cells, this could potentially explain the difference in engraftment. So the authors should perform a simple experiment of cell viability to assess cell death or cell lysis before and after passing through such a small needle, to make sure cell size and cell concentration/density does not negatively impact on the final outcome.

3) Graphs with statistical analysis of transplants need to specify the data points / N values as otherwise is difficult to interpret those numbers.

4) The main finding of the study might be overstated in the title, as in actual fact the absolute differences in dystrophin positive fibers per diaphragm is minimal, as shown in figure 4 d-e. It also unclear how such small numbers might result in such a large statistical significance: please clarify, add N values and consider amending the title into something more factual/descriptive/cautious (e.g. Transplantation and engraftment dynamics of mouse and human myogenic cells in the diaphragm of a mouse model of Duchenne muscular dystrophy).

Reviewer #2: In this manuscript, Miura and colleagues report a technical strategy to enhance the engraftment efficiency of iPS cell-derived muscle stem cells in the diaphragm of a mouse model for Duchenne muscular dystrophy by using an injectable hyaluronic acid-gelatin solution. Although the topic is of interest, the manuscript is of poor quality, presenting many weaknesses and inconsistencies. In addition, this seems more like an initial draft of a manuscript than the final version (missing experimental details and importantly, barely describing results).

Specific comments:

1- Fig. 1a: It is impossible to see the presence of PAX7 positive cells as alluded in Fig. 1b.

2- There is no evidence that the satellite cells are expressing GFP after sorting. The authors are not using GFP to sort satellite cells, and do not show GFP after 3 days in culture.

3- For the transplantation involving satellite cells and myoblasts, the authors quantify the number of fibers per GFP area. Does it correspond to each injection point? The GFP signal looks greater in the image showing the whole diaphragm when compared to the actual number of fibers (autofluorescence?).

4- Fig. 1c-d: It is hard to tell where exactly cells were injected (panel c, left). Also, many GFP+ myofibers are dystrophin negative. How do the authors explain this discrepancy? How about Pax7 staining? Not clear what we should be looking at for this. In addition, this experiment is missing proper controls.

5- Page 14, line 221: The authors refer to unpublished results for the proof-of-concept that used immortalized myoblasts are able to contribute to muscle regeneration in vivo, but this information seems critical for the present manuscript since the authors barely see engraftment in the diaphragm (5 fibers is negligible). The authors barely describe these results.

6- Figure 2: Same issue as figure 1. Most fibers do not express DYSTROPHIN. The number of mice per experimental group is missing.

7- Experiments with hyaluronic acid-gelatin solution are extremely weak. The authors inject immortalized myoblast into the TA to identify this combination, then, when translating into the diaphragm, they use myoblast first and just quantify the GFP signal, they don t show the number of fibers. Why testing human immortalized myoblasts into the TA instead of the diaphragm? There is no evidence that the TA needs extra-help since it is not a moving muscle. This brings another point, did this solution improve the engraftment of mouse satellite cells into the diaphragm? When they tested the hyaluronic acid-gelatin solution in the context of hiPS cell-derived stem cells, the engraftment goes from 1 fiber to 4 fibers: very poor.

8- The bottom line is that there is virtually no engraftment with human cells (immortalized myoblasts and iPSC-derived muscle stem cells), regardless of hyaluronic acid-gelatin solution (5 donor-derived fibers at most, keeping in mind no dystrophin staining was used here). Therefore, the title of the study is misleading, and the results do not support the interpretation of the manuscript.

Minor points:

1- A brief description of the myoblast cell line and the generation of iPS cell-derived myogenic cells should be provided. The reader should not need to look for the author’s previous publications. Because of this lack of information, the description of flow cytometry is meaningless. This section starts as: “...After day 84 of the MuSC induction, the cells….”. The reader has no idea what the authors are referring to.

2- It is not clear whether these invasive studies were performed under an approved animal protocol. This is not mentioned.

3- Description of engraftment analysis on page 11 only mention human SPECTRIN. Incomplete information.

4- Page 9, line 135: can the authors clarify what do they mean with the following statement? “Injection into the diaphragm was recognized by expansion of the injection area”.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 4;17(4):e0266391. doi: 10.1371/journal.pone.0266391.r002

Author response to Decision Letter 0

10 Dec 2021

Reviewer #1

Major Concern:

Q1: If diaphragm movements affect cell engraftment, why is this not impacting on mouse MuSC engraftment as well?

A1: In fact, we believe that diaphragm movement does affect the engraftment of primary MuSCs. A previous study (Didier Montarras et al, Science, 2005) reported the transplantation of 1×104 satellite cells into the TA. This number of cells was the same as the number in our study, but the number of fibers derived from the engrafted cells in the TA was nearly ten times higher (301 fibers) than our observations of the diaphragm (40 fibers). Although these data are not comparable, the findings indicate that movement of the diaphragm affects engraftment.

Q2: Authors use a 33G needle for their injections. This is a very small gauge which could potentially lysate the cell suspension being delivered. As human cells are larger in size than mouse cells, this could potentially explain the difference in engraftment. So the authors should perform a simple experiment of cell viability to assess cell death or cell lysis before and after passing through such a small needle, to make sure cell size and cell concentration/density does not negatively impact on the final outcome.

A2: Following the comment, we carried out additional experiments to validate cell proliferation in vitro in 3 groups: 1) passing through the 33G needle and cultured, 2) passing through the needle with a polymer and cultured, and 3) cultured without passing through the needle.

After passing through the needle, the proliferation of primary satellite cells and iMuSCs was decreased, but that of immortalized cells, Hu5/KD3, was not affected.

Moreover, the polymer solution H2G8 increased the cell proliferation of iMuSCs compared with the polymer-free group. We added these results to Fig. 5 and discuss the effects of passing the cells through the needle and the polymer solution on cell proliferation. The positive effect of the polymer suggests a way to enhance the engraftment efficiency of iMuSCs in the diaphragm.

Q3: Graphs with statistical analysis of transplants need to specify the data points / N values as otherwise is difficult to interpret those numbers.

A3: We added N values to the legends of Fig. 2B, 3A, 3C, and 4D.

Q4: The main finding of the study might be overstated in the title, as in actual fact the absolute differences in dystrophin positive fibers per diaphragm is minimal, as shown in figure 4 d-e. It also unclears how such small numbers might result in such a large statistical significance: please clarify, add N values, and consider amending the title into something more factual/descriptive/cautious (e.g., Transplantation and engraftment dynamics of mouse and human myogenic cells in the diaphragm of a mouse model of Duchenne muscular dystrophy)

A4: We thank the reviewer for the comment and agree the title was overstated. Therefore, we changed the title to “Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice”. In the study, we focused on iMuSC transplantation into the diaphragm rather than a comparison with donor cell engraftment. The transplantation of primary satellite cells was successful, but that of iMuSCs without polymer solution (Medium group) was poor, indicating that the protocol for the iMuSC transplantation into the diaphragm needs optimization. H2G8 modestly enhanced the engraftment. We also found the type of polymer influenced the proportion of no h-SPECTRIN positive fibers: 0.56 (Medium group), 0.69 (A2G8 group) and 0.15 (H2G8 group). Thus, polymers are one step at optimizing iMuSC transplantation into the diaphragm.

We also added N values to the legend of Fig. 4d as noted in our reply to Comment #3.

Reviewer #2

Major Concern:

Q1: Fig. 1a: It is impossible to see the presence of PAX7 positive cells as alluded in Fig. 1b.

A1: We present the ICC staining data separately in Fig. 1A of the revised manuscript to show PAX7 positive cells clearly.

Q2: There is no evidence that the satellite cells are expressing GFP after sorting. The authors are not using GFP to sort satellite cells, and do not show GFP after 3 days in culture.

A2: We added flow cytometry data as supplemental figure S1 to show that the SM/C-2.6 positive lineage marker negative population (purple dots) was GFP positive. We also added the ICC data of GFP to Fig. 1A.

Q3: For the transplantation involving satellite cells and myoblasts, the authors quantify the number of fibers per GFP area. Does it correspond to each injection point? The GFP signal looks greater in the image showing the whole diaphragm when compared to the actual number of fibers (autofluorescence?).

A3: As the reviewer pointed out, the GFP signal looks stronger in the image with the whole diaphragm. Due to the CAG promoter, the EGFP signal is very strong in the primary satellite cells we used. Therefore, the GFP signal was very high.

Q4: Fig. 1c-d: It is hard to tell where exactly cells were injected (panel c, left). Also, many GFP+ myofibers are dystrophin negative. How do the authors explain this discrepancy? How about Pax7 staining? Not clear what we should be looking at for this. In addition, this experiment is missing proper controls.

A4: We apologize for the incomplete data in our figures. We note the injection area with arrowheads in Fig. 1C. We also provide IHC data separately as Fig. 1D to identify all GFP positive fibers as dystrophin positive. The PAX7 staining data in original Fig. 1D is not included in the revised manuscript. Additionally, we added IHC data of the vehicle injection side in Fig. 1D as a control.

Q5: Page 14, line 221: The authors refer to unpublished results for the proof-of-concept that used immortalized myoblasts are able to contribute to muscle regeneration in vivo, but this information seems critical for the present manuscript since the authors barely see engraftment in the diaphragm (5 fibers is negligible). The authors barely describe these results.

A5: We apologize for our poor explanation. An older report found that Hu5/KD3 are able to contribute to muscle regeneration in vivo (Shiomi et al. Gene Therapy, 2011, cited as ref#21). We cited this paper in the sentence instead of our unpublished data.

Q6: Figure 2: Same issue as figure 1. Most fibers do not express DYSTROPHIN. The number of mice per experimental group is missing.

A6: Thank you for the comment. We measured h-SPECTRIN positive fibers in serial sections of the sample in Fig. 2 and confirmed that many GFP positive myofibers are h-SPECTRIN negative (Fig. R1). Thus, we confirmed that the discrepancy of GFP expression and DYSTROPHIN expression were not due to the insufficient immunostaining. One possibility for this observation is the different expression levels of GFP and DYSTROPHIN. The GFP expression was promoted by the strong EF1a promotor in the piggyBac vector, which was multiply transduced, while DYSTROPHIN expression was promoted using an endogenous DYSTROPHIN promotor. Moreover, an interval of 4 weeks after the transplantation might not be enough to see DYSTROPHIN or h-SPECTRIN positive fibers in the Hu5/KD3 transplantation.

Finally, we added the number of mice per experimental group in the appropriate legends.

Fig. R1.

A representative IHC image of the diaphragm 4 weeks after the transplantation of GFP-transgenic Hu5/KD3. The section was stained with anti-hSPECTRIN antibody (red) and anti-GFP antibody (green). Nuclei were stained with DAPI (blue). Scale bars, 50 μm.

Q7: Experiments with hyaluronic acid-gelatin solution are extremely weak. The authors inject immortalized myoblast into the TA to identify this combination, then, when translating into the diaphragm, they use myoblast first and just quantify the GFP signal, they don t show the number of fibers. Why testing human immortalized myoblasts into the TA instead of the diaphragm? There is no evidence that the TA needs extra-help since it is not a moving muscle. This brings another point, did this solution improve the engraftment of mouse satellite cells into the diaphragm? When they tested the hyaluronic acid-gelatin solution in the context of hiPS cell-derived stem cells, the engraftment goes from 1 fiber to 4 fibers: very poor.

A7: Our aim of this project was to assess the engraftment potential of iMuSCs in the diaphragm of DMD model mice. Therefore, we focused on data regarding iMuSC transplantation into the diaphragm in the revised manuscript and changed the title to: Transplantation of human iPSC derived-muscle stem cells in the diaphragm of a Duchenne muscular dystrophy model mice.

Since the transplantation of primary satellite cells was successful, we concluded that the poor result for the iMuSC transplantation without polymer solution (Medium group) indicates the need to optimize the protocol. H2G8 modestly improved the engraftment, as the proportion of no h-SPECTRIN positive fibers was smaller (0.15 vs. 0.56 for the Medium group and 0.69 for the A2G8 group). However, H2G8 is just one step in the optimization of iMuSC transplantation into the diaphragm.

The use of the TA to assess the polymer solution has some advantages. Since the myofibers of the TA are in one direction, it is easy to quantify their regeneration. We then applied our TA findings to iMuSC transplantation to the diaphragm.

As the reviewer mentioned, it would be interesting to see if H2G8 also enhances the engraftment of primary mouse satellite cells. However, in the revised manuscript, we focused on the efficiency of iMuSC transplantation into the diaphragm rather than on the effect of H2G8.

Q8: The bottom line is that there is virtually no engraftment with human cells (immortalized myoblasts and iPSC-derived muscle stem cells), regardless of hyaluronic acid-gelatin solution (5 donor-derived fibers at most, keeping in mind no dystrophin staining was used here). Therefore, the title of the study is misleading, and the results do not support the interpretation of the manuscript.

A8: We agree that our title was inappropriate. We therefore changed it to: Transplantation of human iPSC derived-muscle stem cells in the diaphragm of a Duchenne muscular dystrophy model mice.

To our knowledge, cell transplantation into the diaphragm of mice has never been reported, and we found iMuSC transplantation especially difficult but could be modestly improved if using a polymer solution.

In the study, we did not use DYSTROPHIN as the marker for the engraftment of iMuSCs, because mdx mice have some revertant fibers that express DYSTROPHIN by natural exon skipping. Such endogenous dystrophin positive fibers make it difficult to assess the engraftment. Therefore, we used human-specific SPECTRIN instead of DSYTROPHIN.

#2 reviewer

Minor concern

Q1: A brief description of the myoblast cell line and the generation of iPS cell-derived myogenic cells should be provided. The reader should not need to look for the author’s previous publications. Because of this lack of information, the description of flow cytometry is meaningless. This section starts as: “...After day 84 of the MuSC induction, the cells….”. The reader has no idea what the authors are referring to.

A1: A brief description was added in the Materials and Methods section. (Page 7, line 108-125)

Q2: It is not clear whether these invasive studies were performed under an approved animal protocol. This is not mentioned.

A2: We added information about the study approval.

(Page 5, line 72-75)

Q3: Description of engraftment analysis on page 11 only mention human SPECTRIN. Incomplete information.

A3: We added the following statement to the description: ‘Myofibers derived from engrafted cells were recognized as h-SPECTRIN positive fibers.’ (Page13, line 207-208).

Q4: Page 9, line 135: can the authors clarify what do they mean with the following statement? “Injection into the diaphragm was recognized by expansion of the injection area”.

A4: We modified the sentence to read: ‘Injection into the diaphragm was recognized by swelling of the injection site.’ (Page10, line158)

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(941.1KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0266391.r003

Decision Letter 1

Julie Dumonceaux

1 Feb 2022

PONE-D-21-27260R1Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice

PLOS ONE

Dear Dr. Sakurai,

I am returning your manuscript with 2 reviews. After reading the reviews and looking at the manuscript, I would like you to prepare a revised manuscript in response to the reviewer comments. I expect it to discuss:

1. the discrepancy of GFP expression and DYSTROPHIN expression observed in figure 2 (including the nuclear domain of Dystrophin);

2. The use of human-specific SPECTRIN Abs instead of DSYTROPHIN Abs;

3. To amend the title of figure 4 and the general discussion / conclusion of the article to better reflect the results obtained (going from 1 to 4 spectrin-positive fibers remains very low).

Please submit your revised manuscript by 14/2/2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

We look forward to receiving your revised manuscript.

Kind regards,

Julie Dumonceaux

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: I am satisfied with the revised version of this manuscript , which has improved in quality and should now be of sufficient quality to be published

Reviewer #2: Unfortunately, the revised manuscript still falls short in convincing the reader that meaningful (real) engraftment has been reached with human cells. How can one refer to regenerative potential when transplantation of Hu5/KD3 cells only shows one green fiber (which is not even co-localized with dystrophin)? The authors did not address my concern regarding iMusc transplantation. The explanation provided for not using dystrophin staining is not convincing. Double staining with dystrophin and spectrin antibodies is very doable. Even if there are some revertant fibers in this mouse model, it is possible to identify donor-derived myobers, if they are existent (thus suggesting, lack of expression of DYS). This reviewer also questions the relevance of finding “4” spectrin positive fibers in dystrophin-deficient mice. When the frequency is so low, it is very possible that similar levels will also be found in the negative control, denoting non-specific binding. This is why it is so important to use multiple antibodies.

In summary, the results involving human engraftment are meaningless because engraftment is very poor (at comparable levels of background staining), and on top of that, the authors are not able to show the rescue of the proper marker (dystrophin) in the recipient DMD mouse model used.

Minor: line 258 "mouse" should be added prior to “primary cells”.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

PLoS One. 2022 Apr 4;17(4):e0266391. doi: 10.1371/journal.pone.0266391.r004

Author response to Decision Letter 1

14 Mar 2022

In the revision, we have amended the title of figure 4 and discussion to reflect our results obtained and added immunostaining data to explain why we used the human-SPECTRIN signal instead of the DYSTROPHIN signal for our analysis. In separate file, we provide our detailed replies to all the reviewers’ comments.

Attachment

Submitted filename: response_to_comment_R2_ver2.docx

Click here for additional data file.^{(1.5MB, docx)}

PLoS One. doi: 10.1371/journal.pone.0266391.r005

Decision Letter 2

Julie Dumonceaux

21 Mar 2022

Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice

PONE-D-21-27260R2

Dear Dr. Sakurai,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Prof Julie Dumonceaux

Academic Editor

PLOS ONE

PLoS One. doi: 10.1371/journal.pone.0266391.r006

Acceptance letter

Julie Dumonceaux

25 Mar 2022

PONE-D-21-27260R2

Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice

Dear Dr. Sakurai:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Julie Dumonceaux

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. FCM analysis of isolated primary satellite cells from mice.

(TIF)

Click here for additional data file.^{(362.3KB, tif)}

S2 Fig. FCM analysis after differentiating iPSCs with a knock-in Venus reporter for PAX7 gene.

(TIF)

Click here for additional data file.^{(249.2KB, tif)}

S1 Table. A list of antibodies used.

(TIF)

Click here for additional data file.^{(179.3KB, tif)}

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(941.1KB, docx)}

Attachment

Submitted filename: response_to_comment_R2_ver2.docx

Click here for additional data file.^{(1.5MB, docx)}

Data Availability Statement

All relevant data are within the paper and its Supporting Information files.

[pone.0266391.ref001] 1.Roberts RG. Dystrophins and dystrobrevins. Genome Biology. 2001;2(4):reviews3006.1. doi: 10.1186/gb-2001-2-4-reviews3006 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref002] 2.Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013;14(6):373–8. Epub 2013/04/24. doi: 10.1038/nrg3460 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref003] 3.Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121–5. Epub 2012/10/26. ; PubMed Central PMCID: PMC3476854. [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref004] 4.McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–61. Epub 2017/11/28. doi: 10.1016/S0140-6736(17)32160-8 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref005] 5.Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8(10):918–28. Epub 2009/08/29. doi: 10.1016/S1474-4422(09)70211-X ; PubMed Central PMCID: PMC2755039. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref006] 6.Echevarría L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163–r72. Epub 2018/05/18. doi: 10.1093/hmg/ddy171 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref007] 7.Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther. 2018;26(10):2337–56. Epub 2018/08/11. doi: 10.1016/j.ymthe.2018.07.011 ; PubMed Central PMCID: PMC6171037. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref008] 8.Sun C, Serra C, Lee G, Wagner KR. Stem cell-based therapies for Duchenne muscular dystrophy. Exp Neurol. 2020;323:113086. Epub 2019/10/23. doi: 10.1016/j.expneurol.2019.113086 ; PubMed Central PMCID: PMC6899334. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref009] 9.Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature. 1989;337(6203):176–9. Epub 1989/01/12. doi: 10.1038/337176a0 [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref010] 10.Xu X, Wilschut KJ, Kouklis G, Tian H, Hesse R, Garland C, et al. Human Satellite Cell Transplantation and Regeneration from Diverse Skeletal Muscles. Stem Cell Reports. 2015;5(3):419–34. Epub 2015/09/10. doi: 10.1016/j.stemcr.2015.07.016 ; PubMed Central PMCID: PMC4618654. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref011] 11.Ikemoto M, Fukada S, Uezumi A, Masuda S, Miyoshi H, Yamamoto H, et al. Autologous transplantation of SM/C-2.6(+) satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Mol Ther. 2007;15(12):2178–85. Epub 2007/08/30. doi: 10.1038/sj.mt.6300295 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref012] 12.Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005;309(5743):2064–7. Epub 2005/09/06. doi: 10.1126/science.1114758 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref013] 13.Zhao M, Tazumi A, Takayama S, Takenaka-Ninagawa N, Nalbandian M, Nagai M, et al. Induced Fetal Human Muscle Stem Cells with High Therapeutic Potential in a Mouse Muscular Dystrophy Model. Stem Cell Reports. 2020;15(1):80–94. Epub 2020/07/04. doi: 10.1016/j.stemcr.2020.06.004 ; PubMed Central PMCID: PMC7363940. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref014] 14.Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010;120(1):11–9. Epub 2010/01/07. doi: 10.1172/JCI40373 ; PubMed Central PMCID: PMC2798695. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref015] 15.Han WM, Mohiuddin M, Anderson SE, García AJ, Jang YC. Co-delivery of Wnt7a and muscle stem cells using synthetic bioadhesive hydrogel enhances murine muscle regeneration and cell migration during engraftment. Acta Biomater. 2019;94:243–52. Epub 2019/06/23. doi: 10.1016/j.actbio.2019.06.025 ; PubMed Central PMCID: PMC6642840. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref016] 16.Masumoto H, Ikuno T, Takeda M, Fukushima H, Marui A, Katayama S, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Scientific reports. 2014;4(1):1–7. doi: 10.1038/srep06716 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref017] 17.Nakajima K, Fujita J, Matsui M, Tohyama S, Tamura N, Kanazawa H, et al. Gelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial Infarction. PLoS One. 2015;10(7):e0133308. Epub 2015/07/18. doi: 10.1371/journal.pone.0133308 ; PubMed Central PMCID: PMC4505846. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref018] 18.Xu L, Guo Y, Huang Y, Xu Y, Lu Y, Wang Z. Hydrogel materials for the application of islet transplantation. J Biomater Appl. 2019;33(9):1252–64. Epub 2019/02/23. doi: 10.1177/0885328219831391 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref019] 19.Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. ’Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997;407(3):313–9. Epub 1997/05/05. doi: 10.1016/s0014-5793(97)00313-x . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref020] 20.Fukada S, Higuchi S, Segawa M, Koda K, Yamamoto Y, Tsujikawa K, et al. Purification and cell-surface marker characterization of quiescent satellite cells from murine skeletal muscle by a novel monoclonal antibody. Exp Cell Res. 2004;296(2):245–55. Epub 2004/05/20. doi: 10.1016/j.yexcr.2004.02.018 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref021] 21.Shiomi K, Kiyono T, Okamura K, Uezumi M, Goto Y, Yasumoto S, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene therapy. 2011;18(9):857–66. doi: 10.1038/gt.2011.44 [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref022] 22.Matsui H, Fujimoto N, Sasakawa N, Ohinata Y, Shima M, Yamanaka S, et al. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. PloS one. 2014;9(8):e104957. doi: 10.1371/journal.pone.0104957 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref023] 23.Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409–12. Epub 2011/04/05. doi: 10.1038/nmeth.1591 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref024] 24.Nalbandian M, Zhao M, Sasaki-Honda M, Jonouchi T, Lucena-Cacace A, Mizusawa T, et al. Characterization of hiPSC-Derived Muscle Progenitors Reveals Distinctive Markers for Myogenic Cell Purification Toward Cell Therapy. Stem Cell Reports. 2021. doi: 10.1016/j.stemcr.2021.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref025] 25.Tabei R, Kawaguchi S, Kanazawa H, Tohyama S, Hirano A, Handa N, et al. Development of a transplant injection device for optimal distribution and retention of human induced pluripotent stem cellderived cardiomyocytes. J Heart Lung Transplant. 2019;38(2):203–14. Epub 2019/01/30. doi: 10.1016/j.healun.2018.11.002 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref026] 26.Anamizu M, Tabata Y. Design of injectable hydrogels of gelatin and alginate with ferric ions for cell transplantation. Acta Biomater. 2019;100:184–90. Epub 2019/10/08. doi: 10.1016/j.actbio.2019.10.001 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref027] 27.Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23(12):H41–56. Epub 2011/03/12. doi: 10.1002/adma.201003963 ; PubMed Central PMCID: PMC3730855. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref028] 28.Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A. 2012;18(7–8):806–15. Epub 2011/10/21. doi: 10.1089/ten.TEA.2011.0391 ; PubMed Central PMCID: PMC3313609. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref029] 29.Ishii K, Sakurai H, Suzuki N, Mabuchi Y, Sekiya I, Sekiguchi K, et al. Recapitulation of Extracellular LAMININ Environment Maintains Stemness of Satellite Cells In Vitro. Stem Cell Reports. 2018;10(2):568–82. Epub 2018/01/18. doi: 10.1016/j.stemcr.2017.12.013 ; PubMed Central PMCID: PMC5830886. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref030] 30.Boonen KJ, Rosaria-Chak KY, Baaijens FP, van der Schaft DW, Post MJ. Essential environmental cues from the satellite cell niche: optimizing proliferation and differentiation. Am J Physiol Cell Physiol. 2009;296(6):C1338–45. Epub 2009/03/27. doi: 10.1152/ajpcell.00015.2009 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref031] 31.Zarei-Kheirabadi M, Sadrosadat H, Mohammadshirazi A, Jaberi R, Sorouri F, Khayyatan F, et al. Human embryonic stem cell-derived neural stem cells encapsulated in hyaluronic acid promotes regeneration in a contusion spinal cord injured rat. Int J Biol Macromol. 2020;148:1118–29. Epub 2020/01/27. doi: 10.1016/j.ijbiomac.2020.01.219 . [DOI] [PubMed] [Google Scholar]

[pone.0266391.ref032] 32.Lin C, Han G, Ning H, Song J, Ran N, Yi X, et al. Glycine Enhances Satellite Cell Proliferation, Cell Transplantation, and Oligonucleotide Efficacy in Dystrophic Muscle. Mol Ther. 2020;28(5):1339–58. Epub 2020/03/27. doi: 10.1016/j.ymthe.2020.03.003 ; PubMed Central PMCID: PMC7210708. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref033] 33.Elhussieny A, Nogami K, Sakai-Takemura F, Maruyama Y, Takemura N, Soliman WT, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR). Stem Cell Res Ther. 2021;12(1):532. Epub 2021/10/11. doi: 10.1186/s13287-021-02594-1 ; PubMed Central PMCID: PMC8501581. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0266391.ref034] 34.Llufrio EM, Wang L, Naser FJ, Patti GJ. Sorting cells alters their redox state and cellular metabolome. Redox Biol. 2018;16:381–7. Epub 2018/04/09. doi: 10.1016/j.redox.2018.03.004 ; PubMed Central PMCID: PMC5952879. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice

Yasutomo Miura

Mase Sato

Toshie Kuwahara

Tomoki Ebata

Yasuhiko Tabata

Hidetoshi Sakurai

Roles

Abstract

Introduction

Materials and methods

Study approval

Animals

Cells

Primary satellite cells

Hu5/KD3

Human iPSC culture and differentiation

Flow cytometry sorting of muscle stem cells

Preparation of injectable mixed polymer solution

Measurement velocity of polymer solution

Transplantation to the diaphragm

Transplantation to the tibialis anterior

Immunocytochemistry

Immunohistochemistry

Observation of GFP signals

Statistical analysis

Engraftment efficiency analysis

Validation of cell proliferation in vitro after passing through the transplantation needle

Results

Primary satellite cells regenerate dystrophic diaphragm in NOG-mdx mice

Fig 1. Primary satellite cells engrafted in the diaphragm.

Transplantation of human immortalized myoblasts into the diaphragm shows limited engraftment

Fig 2. Human immortalized myoblasts in the diaphragm show limited engraftment.

Cell suspension with mixed polymer solution improves the engraftment efficiency of Hu5/KD3

Fig 3. Injectable mixed polymer solution improves engraftment efficiency in the TA.

Mixed hyaluronic acid-gelatin solution reduces the frequency of iMuSC engraftment failure in the diaphragm of NOG-mdx mice

Fig 4. H2G8 reduces the frequency of iMuSC engraftment failure in the diaphragm of NOG-mdx mice.

Mixed hyaluronic acid-gelatin solution improves the proliferation of iMuSCs

Fig 5. H2G8 increases the proliferation of iMuSCs.

Discussion

Conclusion

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Julie Dumonceaux

Roles

Author response to Decision Letter 0

Decision Letter 1

Julie Dumonceaux

Roles

Author response to Decision Letter 1

Decision Letter 2

Julie Dumonceaux

Roles

Acceptance letter

Julie Dumonceaux

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases